{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T01:38:42Z","timestamp":1767145122237,"version":"build-2238731810"},"update-to":[{"DOI":"10.1016\/j.anl.2020.02.018","type":"withdrawal","label":"Withdrawal","source":"publisher","updated":{"date-parts":[[2020,6,4]],"date-time":"2020-06-04T00:00:00Z","timestamp":1591228800000}}],"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Auris Nasus Larynx"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.anl.2020.02.018","type":"journal-article","created":{"date-parts":[[2020,6,4]],"date-time":"2020-06-04T16:57:16Z","timestamp":1591289836000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["DUPLICATE: Overall survival and PD-L1 expression in patients with recurrent or metastatic head and neck cancer treated with nivolumab"],"prefix":"10.1016","author":[{"given":"Isaku","family":"Okamoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyoaki","family":"Tsukahara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.anl.2020.02.018_bib0001","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa0802656","article-title":"Platinum-based chemotherapy plus cetuximab in head and neck cancer","volume":"359","author":"Vermorken","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anl.2020.02.018_bib0002","year":"2019","journal-title":"National Comprehensive Cancer Network, Version 1."},{"key":"10.1016\/j.anl.2020.02.018_bib0003","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anl.2020.02.018_bib0004","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1080\/00016489.2019.1648867","article-title":"Efficacy and safety of nivolumab in 100 patients with recurrent or metastatic head and neck cancer - a retrospective multicentre study","volume":"139","author":"Okamoto","year":"2019","journal-title":"Acta Otolaryngol"},{"key":"10.1016\/j.anl.2020.02.018_bib0005","doi-asserted-by":"crossref","DOI":"10.1007\/s40261-019-00846-w","article-title":"Nivolumab-induced recurrence of rheumatoid arthritis in a patient with metastatic gastric adenocarcinoma","author":"Nishikawa","year":"2019","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.anl.2020.02.018_bib0006","first-page":"11","article-title":"Real-world outcomes and prognostic factors in patients receiving nivolumab therapy for recurrent or metastatic head and neck carcinoma","author":"Hori","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.anl.2020.02.018_bib0007","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1001\/jamaoncol.2017.2925","article-title":"Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer","volume":"4","author":"Haratani","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.anl.2020.02.018_bib0008","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1016\/j.jtho.2017.08.022","article-title":"Early immune-related adverse events and association with outcome in advanced non-small cell lung cancer patients treated with nivolumab: a prospective cohort study","volume":"12","author":"Teraoka","year":"2017","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.anl.2020.02.018_bib0009","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1158\/1078-0432.CCR-16-1761","article-title":"PD-L2 expression in human tumors: relevance to anti-PD-1 therapy in cancer","volume":"23","author":"Yearley","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.anl.2020.02.018_bib0010","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1158\/1078-0432.CCR-14-1905","article-title":"Stromal CD8+ T-cell density-a promising supplement to TNM staging in non-small cell lung cancer","volume":"21","author":"Donnem","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.anl.2020.02.018_bib0011","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1002\/hed.25737","article-title":"Monitoring the neutrophil-to-lymphocyte ratio may be useful for predicting the anticancer effect of nivolumab in recurrent or metastatic head and neck cancer","volume":"41","author":"Yasumatsu","year":"2019","journal-title":"Head Neck"},{"key":"10.1016\/j.anl.2020.02.018_bib0012","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.anl.2020.02.018_bib0013","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/annonc\/mdz003","article-title":"Novel patterns of response under immunotherapy","volume":"30","author":"Borcoman","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.anl.2020.02.018_bib0014","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software 'EZR' for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.anl.2020.02.018_bib0015","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anl.2020.02.018_bib0016","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.anl.2020.02.018_bib0017","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1470-2045(15)70054-9","article-title":"Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial","volume":"16","author":"Rizvi","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.anl.2020.02.018_bib0018","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anl.2020.02.018_bib0019","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anl.2020.02.018_bib0020","doi-asserted-by":"crossref","first-page":"3208","DOI":"10.1002\/cncr.32190","article-title":"Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: a subgroup analysis of a randomized phase 3 clinical trial","volume":"125","author":"Haddad","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.anl.2020.02.018_bib0021","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1158\/1078-0432.CCR-16-1741","article-title":"Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1\/PD-L1","volume":"23","author":"Champiat","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.anl.2020.02.018_bib0022","doi-asserted-by":"crossref","first-page":"4242","DOI":"10.1158\/1078-0432.CCR-16-3133","article-title":"Hyperprogressors after immunotherapy: analysis of genomic alterations associated with accelerated growth rate","volume":"23","author":"Kato","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.anl.2020.02.018_bib0023","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1093\/annonc\/mdx178","article-title":"Hyperprogression during anti-PD-1\/PD-L1 therapy in patients with recurrent and\/or metastatic head and neck squamous cell carcinoma","volume":"28","author":"Saada-Bouzid","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.anl.2020.02.018_bib0024","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.anl.2020.02.018_bib0025","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.anl.2020.02.018_bib0026","doi-asserted-by":"crossref","first-page":"875","DOI":"10.3892\/or.2014.3275","article-title":"Antibody therapies for melanoma: new and emerging opportunities to activate immunity (Review)","volume":"32","author":"Malas","year":"2014","journal-title":"Oncol Rep"},{"key":"10.1016\/j.anl.2020.02.018_bib0027","doi-asserted-by":"crossref","first-page":"501","DOI":"10.18632\/aging.101756","article-title":"Prognostic value of immune checkpoint molecules in head and neck cancer: a meta-analysis","volume":"11","author":"Jia","year":"2019","journal-title":"Aging (Albany NY)"},{"key":"10.1016\/j.anl.2020.02.018_bib0028","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anl.2020.02.018_bib0029","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.anl.2020.02.018_bib0030","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/PAI.0000000000000256","article-title":"Development of an automated PD-L1 immunohistochemistry (IHC) assay for non-small cell lung cancer","volume":"23","author":"Phillips","year":"2015","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.1016\/j.anl.2020.02.018_bib0031","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1093\/annonc\/mdv489","article-title":"Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies","volume":"27","author":"Ilie","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.anl.2020.02.018_bib0032","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1002\/hed.25737","article-title":"Monitoring the neutrophil-to-lymphocyte ratio may be useful for predicting the anticancer effect of nivolumab in recurrent or metastatic head and neck cancer","volume":"41","author":"Yasumatsu","year":"2019","journal-title":"Head Neck"}],"updated-by":[{"DOI":"10.1016\/j.anl.2020.02.018","type":"withdrawal","label":"Withdrawal","source":"publisher","updated":{"date-parts":[[2020,6,4]],"date-time":"2020-06-04T00:00:00Z","timestamp":1591228800000}}],"container-title":["Auris Nasus Larynx"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0385814620300900?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0385814620300900?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T22:56:11Z","timestamp":1759877771000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0385814620300900"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":32,"alternative-id":["S0385814620300900"],"URL":"https:\/\/doi.org\/10.1016\/j.anl.2020.02.018","relation":{},"ISSN":["0385-8146"],"issn-type":[{"value":"0385-8146","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"DUPLICATE: Overall survival and PD-L1 expression in patients with recurrent or metastatic head and neck cancer treated with nivolumab","name":"articletitle","label":"Article Title"},{"value":"Auris Nasus Larynx","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anl.2020.02.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Oto-Rhino-Laryngological Society of Japan Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}